ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Enhancing Anti-Tumor Effects of Engineered Extracellular Vesicles via Endocytosis Route Switching and Interferon Response Suppression.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Extracellular vesicles in targeted drug delivery: from biological functions to surface engineering.Molecular biomedicine · 2026Review
- Bioengineering of extracellular vesicles with scaffold proteins for drug delivery.Journal of nanobiotechnology · 2026Review
- From Uptake to Therapeutic Function in Engineered Exosome Delivery Systems.Research (Washington, D.C.) · 2026Review
- Enhancing Anti-Tumor Effects of Engineered Extracellular Vesicles via Endocytosis Route Switching and Interferon Response Suppression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Engineered extracellular vesicles (EVs) represent a promising therapeutic strategy with many applications in cancer therapy. EVs derived from engineered tumor-targeting killer cells, such as chimeric antigen receptor (CAR)-T cells. However, the application of CAR-T-EVs is limited by several drawbacks. This study shows that engineered EVs with potent cancer-targeting and killing abilities can be generated from easily manipulable non-killer cells, providing a solution to overcome the limitations of CAR-T-EVs. It is found that EVs derived from non-killer cells such as CD19-targeting 293 cells possess target cell killing capacities comparable to those derived from CD19-CAR-T cells. A technique is developed to ensure the presence of sufficient targeting modules on the EV surface using a chimeric CD8-CD63/CD81 transmembrane region. Uptake of CD19-targeting EVs by target cells can be optimized by switching the route of CD19 endocytosis from clathrin-mediated endocytosis (CME) to aggregation-dependent endocytosis (ADE), leading to lysosomal degradation of the CD19/EVs complex. Degradation of the EVs leads to impairment in the IFN response and subsequent enhancement in EV uptake by target cells, creating a potent feedback cycle. CD19 depletion results in the disruption of the CD19-AKT-Myc pathway in the target cells, enhancing the killing capacity both in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.